Manjaro
product on 2 shows · 4 statements across 2 episodes
4 statements about Manjaro, every show
Dave Ricks predicts Mounjaro revenues will drop to zero in the 2030s
“So, in 20, 30 something, Manjaro will go to zero.”
Eli Lilly's Mounjaro demonstrated a 93% reduction in pre-diabetes conversion
“So we did that with Manjaro and showed a 93% reduction in conversion from pre-diabetes to diabetes.”
Israetel: GLP-1 drugs curb obesity primarily by lowering genetic food drive
“New medications like Ozempic, Trisapatide, et cetera, Manjaro, all those things. While, why they were some of the only things to really take a big chunk out of obesity is because they take your, whatever genetic food drive and palatability drive you have, how …”
Israetel: Tirzepatide outperforms Ozempic, with more potent fifth-gen GLP drugs in trials
“Technically it's a third generation GLP drug, but fourth gen is Trisapatide. It's already on the market, Manjaro. Fewer side effects, bigger primary effect. There are fifth gen drugs currently in FDA approval process, which make Ozempic look like a starter pac…”